Basic Information
| RNALocate ID: | RLID:11002214 |
| RNA Symbol: | hsa-miR-200c-3p |
| Localization: | Microvesicle |
RNA Information
| RNA Name: | hsa-miR-200c |
| RNA ID: | miRBase:MIMAT0000617 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 23539611 |
| Tissue/Cell Line: | Seminal plasma |
| Method: | Microarray |
| Description: | In order to assess the reversibility of post-vasectomy miRNA sequelae, we investigated whether SMV miRNAs altered by vasectomy could be retrieved in SMVs from normospermic vasovasostomized donors. miRNA microarray profiling performed on SMVs from normal, vasectomized and vasovasostomized donors identified 313 miRNAs whose intensity was above the threshold of detection. Among these miRNAs, 293 were detected in samples from normal donors, 275 in vasectomized donors and 298 in vasovasostomized donors (Fig. 3, Supplementary data, Table SIV). Data are collected from Table S4. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001951 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:01001952 | Nucleolus | Breast adenocarcinoma cells (MCF-7) | 24918059 |
| RLID:01001953 | Nucleus | Colon adenocarcinoma cells | 20864815 |
| RLID:11002205 | Exosome | Urine | 26576778 |
| RLID:11002206 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
| RLID:11002207 | Exosome | Jurkat-derived T cell line (J77cl20) | 21505438 |
| RLID:11002208 | Exosome | Ascites fluid|Pleural effusion | 21601258 |
| RLID:11002209 | Exosome | Renal cancer cells | 21670082 |
| RLID:11002210 | Exosome | Brain tissue | 23382797 |
| RLID:11002211 | Exosome | Plasma | 23663360 |
| RLID:11002212 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
| RLID:11002213 | Extracellular vesicle | Plasma | 32498409 |
| RLID-D:11000105 | Exosome | Breast milk|Colon tissue|Seminal fluid|Tongue tissue | |
| RLID-D:11000392 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-200c-3p | Idiopathic pulmonary fibrosis | MNDR-E-MI-26335 |
| MNDR | hsa-miR-200c-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-26336 |
| MNDR | hsa-miR-200c-3p | Oral squamous cell carcinoma | MNDR-E-MI-26337 |
| MNDR | hsa-miR-200c-3p | Large cell neuroendocrine cancer | MNDR-E-MI-26338 |
| MNDR | hsa-miR-200c-3p | B cell lymphoma of malt type | MNDR-E-MI-26339 |
| MNDR | hsa-miR-200c-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-26340 |
| MNDR | hsa-miR-200c-3p | Ovarian clear cell carcinoma | MNDR-E-MI-26341 |
| MNDR | hsa-miR-200c-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-26342 |
| MNDR | hsa-miR-200c-3p | Lymphoma | MNDR-E-MI-26343 |
| MNDR | hsa-miR-200c-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-26344 |
| MNDR | hsa-miR-200c-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-26345 |
| MNDR | hsa-miR-200c-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-26346 |
| MNDR | hsa-miR-200c-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-26347 |
| MNDR | hsa-miR-200c-3p | Her2-receptor positive breast cancer | MNDR-E-MI-26348 |
| MNDR | hsa-miR-200c-3p | Triple negative breast cancer | MNDR-E-MI-26349 |
| MNDR | hsa-miR-200c-3p | Breast cancer luminal | MNDR-E-MI-26350 |
| MNDR | hsa-miR-200c-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-26351 |
| MNDR | hsa-miR-200c-3p | B cell acute lymphoblastic leukemia | MNDR-E-MI-26352 |
| MNDR | hsa-miR-200c-3p | Prostate cancer | MNDR-E-MI-26353 |
| MNDR | hsa-miR-200c-3p | Prostate carcinoma | MNDR-E-MI-26354 |
| MNDR | hsa-miR-200c-3p | Gastric cancer | MNDR-E-MI-26355 |
| MNDR | hsa-miR-200c-3p | Alzheimer disease | MNDR-E-MI-26356 |
| MNDR | hsa-miR-200c-3p | Bladder cancer | MNDR-E-MI-26357 |
| MNDR | hsa-miR-200c-3p | Dysautonomia familial | MNDR-E-MI-26358 |
| MNDR | hsa-miR-200c-3p | Head and neck cancer | MNDR-E-MI-26359 |
| MNDR | hsa-miR-200c-3p | Leukemia | MNDR-E-MI-26360 |
| MNDR | hsa-miR-200c-3p | Leiomyoma | MNDR-E-MI-26361 |
| MNDR | hsa-miR-200c-3p | Huntington disease | MNDR-E-MI-26362 |
| MNDR | hsa-miR-200c-3p | Chorea | MNDR-E-MI-26363 |
| MNDR | hsa-miR-200c-3p | Cardiovascular disease | MNDR-E-MI-26364 |
| MNDR | hsa-miR-200c-3p | Lung cancer | MNDR-E-MI-26365 |
| MNDR | hsa-miR-200c-3p | Endometrial cancer | MNDR-E-MI-26366 |
| MNDR | hsa-miR-200c-3p | Down syndrome | MNDR-E-MI-26367 |
| MNDR | hsa-miR-200c-3p | Parkinson disease | MNDR-E-MI-26368 |
| MNDR | hsa-miR-200c-3p | Primary pulmonary hypertension | MNDR-E-MI-26369 |
| MNDR | hsa-miR-200c-3p | Breast cancer | MNDR-E-MI-26370 |
| MNDR | hsa-miR-200c-3p | Cancer | MNDR-E-MI-26371 |
| MNDR | hsa-miR-200c-3p | Thyroid cancer | MNDR-E-MI-26372 |
| MNDR | hsa-miR-200c-3p | Pituitary neoplasms | MNDR-E-MI-26373 |
| MNDR | hsa-miR-200c-3p | Pancreatic cancer | MNDR-E-MI-26374 |
| MNDR | hsa-miR-200c-3p | Hepatitis C | MNDR-E-MI-26375 |
| MNDR | hsa-miR-200c-3p | Melanoma | MNDR-E-MI-26376 |
| MNDR | hsa-miR-200c-3p | Williams syndrome | MNDR-E-MI-26377 |
| MNDR | hsa-miR-200c-3p | Nephroblastoma | MNDR-E-MI-26378 |
| MNDR | hsa-miR-200c-3p | Colon cancer | MNDR-E-MI-26379 |
| MNDR | hsa-miR-200c-3p | Ischemic attack transient | MNDR-E-MI-26380 |
| MNDR | hsa-miR-200c-3p | Colon adenocarcinoma | MNDR-E-MI-26381 |
| MNDR | hsa-miR-200c-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-26382 |
| MNDR | hsa-miR-200c-3p | Familial ovarian cancer | MNDR-E-MI-26383 |
| MNDR | hsa-miR-200c-3p | Acromegaly | MNDR-E-MI-26384 |
| MNDR | hsa-miR-200c-3p | Prostate adenocarcinoma | MNDR-E-MI-26385 |
| MNDR | hsa-miR-200c-3p | Kidney cancer | MNDR-E-MI-26386 |
| MNDR | hsa-miR-200c-3p | Endometrial adenocarcinoma | MNDR-E-MI-26387 |
| MNDR | hsa-miR-200c-3p | Endometrial carcinoma | MNDR-E-MI-26388 |
| MNDR | hsa-miR-200c-3p | Carcinoma ductal breast | MNDR-E-MI-26389 |
| MNDR | hsa-miR-200c-3p | Glioblastoma | MNDR-E-MI-26390 |
| MNDR | hsa-miR-200c-3p | Glioma | MNDR-E-MI-26391 |
| MNDR | hsa-miR-200c-3p | Epilepsy temporal lobe | MNDR-E-MI-26392 |
| MNDR | hsa-miR-200c-3p | Breast carcinoma | MNDR-E-MI-26393 |
| MNDR | hsa-miR-200c-3p | Liver neoplasms | MNDR-E-MI-26394 |
| MNDR | hsa-miR-200c-3p | Cervical adenocarcinoma | MNDR-E-MI-26395 |
| MNDR | hsa-miR-200c-3p | Ovarian adenocarcinoma | MNDR-E-MI-26396 |
| MNDR | hsa-miR-200c-3p | Gastric adenocarcinoma | MNDR-E-MI-26397 |
| MNDR | hsa-miR-200c-3p | Cervical squamous cell carcinoma | MNDR-E-MI-26398 |
| MNDR | hsa-miR-200c-3p | Pituitary adenoma | MNDR-E-MI-26399 |
| MNDR | hsa-miR-200c-3p | Lung squamous cell carcinoma | MNDR-E-MI-26400 |
| MNDR | hsa-miR-200c-3p | Non-small cell lung cancer | MNDR-E-MI-26401 |
| MNDR | hsa-miR-200c-3p | Lung adenocarcinoma | MNDR-E-MI-26402 |
| MNDR | hsa-miR-200c-3p | Thyroid carcinoma | MNDR-E-MI-26403 |
| MNDR | hsa-miR-200c-3p | Ovarian carcinoma | MNDR-E-MI-26404 |
| MNDR | hsa-miR-200c-3p | Bladder urothelial carcinoma | MNDR-E-MI-26405 |
| MNDR | hsa-miR-200c-3p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-26406 |
| MNDR | hsa-miR-200c-3p | Carcinoma renal cell | MNDR-E-MI-26407 |
| MNDR | hsa-miR-200c-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-26408 |
| MNDR | hsa-miR-200c-3p | Clear cell renal cell carcinoma | MNDR-E-MI-26409 |
| MNDR | hsa-miR-200c-3p | Large cell carcinoma | MNDR-E-MI-26410 |
| MNDR | hsa-miR-200c-3p | Biliary tract cancer | MNDR-E-MI-26411 |
| MNDR | hsa-miR-200c-3p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-26412 |
| MNDR | hsa-miR-200c-3p | Cholangiocarcinoma | MNDR-E-MI-26413 |
| MNDR | hsa-miR-200c-3p | Esophageal cancer | MNDR-E-MI-26414 |
| MNDR | hsa-miR-200c-3p | Uterus leiomyosarcoma | MNDR-E-MI-26415 |
| MNDR | hsa-miR-200c-3p | Prolactinoma | MNDR-E-MI-26416 |
| MNDR | hsa-miR-200c-3p | Lung small cell carcinoma | MNDR-E-MI-26417 |
| MNDR | hsa-miR-200c-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-26418 |
| MNDR | hsa-miR-200c-3p | Testicular germ cell cancer | MNDR-E-MI-26419 |
| MNDR | hsa-miR-200c-3p | T acute lymphoblastic leukemia | MNDR-E-MI-26420 |
| MNDR | hsa-miR-200c-3p | Acute t cell leukemia | MNDR-E-MI-26421 |
| MNDR | hsa-miR-200c-3p | Ovarian endometrial cancer | MNDR-E-MI-26422 |
| MNDR | hsa-miR-200c-3p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-26423 |
| MNDR | hsa-miR-200c-3p | Breast invasive carcinoma | MNDR-E-MI-26424 |
| MNDR | hsa-miR-200c-3p | Hepatocellular carcinoma | MNDR-E-MI-26425 |
| MNDR | hsa-miR-200c-3p | Familiar ovarian carcinoma | MNDR-E-MI-26426 |
| MNDR | hsa-miR-200c-3p | B-cell lymphoma | MNDR-E-MI-26427 |
| MNDR | hsa-miR-200c-3p | Retinoblastoma | MNDR-E-MI-26428 |
| MNDR | hsa-miR-200c-3p | Hodgkin lymphoma | MNDR-E-MI-26429 |
| MNDR | hsa-miR-200c-3p | Burkitt lymphoma | MNDR-E-MI-26430 |
| MNDR | hsa-miR-200c-3p | Crohn disease | MNDR-E-MI-26431 |
| MNDR | hsa-miR-200c-3p | Skin cutaneous melanoma | MNDR-E-MI-26432 |
| MNDR | hsa-miR-200c-3p | Skin melanoma | MNDR-E-MI-26433 |
| MNDR | hsa-miR-200c-3p | Systemic lupus erythematosus | MNDR-E-MI-26434 |
| MNDR | hsa-miR-200c-3p | Acute myelocytic leukemia | MNDR-E-MI-26435 |
| MNDR | hsa-miR-200c-3p | Colorectal cancer | MNDR-E-MI-26436 |
| MNDR | hsa-miR-200c-3p | Nasopharynx carcinoma | MNDR-E-MI-26437 |
| MNDR | hsa-miR-200c-3p | Multiple myeloma | MNDR-E-MI-26438 |
| MNDR | hsa-miR-200c-3p | Ovarian epithelial cancer | MNDR-E-MI-26439 |
| MNDR | hsa-miR-200c-3p | Epstein-barr virus infections | MNDR-E-MI-26440 |
| MNDR | hsa-miR-200c-3p | Non-alcoholic fatty liver disease | MNDR-E-MI-26441 |
| MNDR | hsa-miR-200c-3p | Breast cancer her3+ negative | MNDR-E-MI-26442 |
| MNDR | hsa-miR-200c-3p | Renal childhood neoplasms | MNDR-E-MI-26443 |
| MNDR | hsa-miR-200c-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-26444 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ABCA2 | Homo sapiens | RR00022406 |
TOP